Cisen Pharmaceutical603367.SHValuation Analysis
Based on the blended 10-year P/E and P/B percentiles, the stock currently sits in the “Deeply Undervalued” zone.
As of Oct 19, 2026, Cisen Pharmaceutical (603367.SH) trades at a P/E of 13.50x, P/B of 0.97x, P/S of 1.83x, and a dividend yield of 2.55%.
Longitudinal percentile comparison: P/E sits at the 27th percentile over the trailing 10Y window (vs. 45th percentile over 3Y); P/B sits at the 2nd percentile over the trailing 10Y window (vs. 7th percentile over 3Y); P/S sits at the 58th percentile over the trailing 10Y window (vs. 58th percentile over 3Y).
Cross-sectional valuation: its P/E ranks at the 6th percentile within its industry and the 11th percentile across the broader market.
Shareholder return highlight: Total Shareholder Yield is 2.55%, ranking at the 68th percentile over the trailing 20Y window.
The P/E and P/B percentiles diverge here, differing by 24.9 points — relying on either metric alone could be misleading. Its P/E percentile is roughly the same whether measured against the industry or the broader market. Shareholder returns here are driven almost entirely by cash dividends, with minimal contribution from buybacks. Cisen Pharmaceutical operates in the Medicine sector. Data refreshes weekly and is for reference only, not investment advice.
Also listed as: SHA: 603367 · SSE: 603367 · 603367
Want the full picture on whether Cisen Pharmaceutical (603367.SH) is under- or over-valued? See the full 3Y / 5Y / 10Y / 20Y P/E, P/B, P/S, Dividend Yield & Total Shareholder Yield percentile matrix and the interactive ECharts trend chart on this page.
Historical Percentiles by Metric
| Metric | Current | Market Percentile | Industry Percentile | 3Y Pctl | 5Y Pctl | 10Y Pctl | 20Y Pctl |
|---|---|---|---|---|---|---|---|
| P/E (TTM) | 13.50 | ||||||
| P/B (MRQ) | 0.97 | ||||||
| P/S (TTM) | 1.83 | ||||||
| Dividend Yield | 2.55% | ||||||
| Buyback + Div Yield | 2.55% |